Cholesterol Treatment Trialists Collaboration. Efficacy and Safety of more intensive lowering of LDL-cholesterol: A meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet, 2010; 376:1670–1681.
2.
GinsbergHN, ElamMB, LovatoLC, et al.Effects of Combined lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362:1563–1574.
3.
BodenWE, ProbstfieldJL, AndersonT, et al.Niacin in patients with low HDL-cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365:2255–2267.
4.
LandrayMJ, HaynesR, HopwellJC, et al.Effects of extended-release niacin with Laropiprant in high risk patients. N Engl J Med, 2014; 371:203–212.
5.
YokoyamaM, OrigasaH, MatsuzakiM, et al. Effect of eicosapentaenioc acid on major coronary events in hypercholesterolemic patients (JELIS). Lancet, 2007, 369:1090–1098.
6.
CannonCP, BlazingMA, GiuglianoRP, et al.Ezetimibe added to statin therapy after Acute coronary syndromes. N Engl J Med, 2015; 372:2387–2397.
7.
BaigentC, LandrayMJ, ReithC, et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chroin kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet, 2011; 377:2181–2192.
8.
SheelyD, JialalI. Strategies to lower LDL-cholesterol in metabolic syndrome: Averting the diabetes risk. Metab Syndr Relat Disord, 2013; 11:149–151.
9.
RidkerPM, CannonCP, MorrowD, et al.C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005; 352:20–28.
10.
The Myocardial Infarction Genetics Consortium Investigators; StitzielNO, WonHH, MorrisonAC, et al.Inactivating mutations in NLC1LI and protection from coronary heart disease. N Engl J Med, 2014; 371:2072–2082.
